Moreover, GSK2606414, an ATP-competitive potent PERK inhibitor, had significant antiproliferative and proapoptotic effects on a broad panel of MM cell lines alone, and in combination with BTZ exerted additive toxic effects, probably through increased proteotoxic stress [171, 180, 182]. Here, EIF2AK3 is linked to Miyoshi myopathy.